NasdaqGM:IRONBiotechs
Assessing Disc Medicine (IRON) Valuation After FDA Complete Response Letter And Shareholder Investigation
Disc Medicine (IRON) is back in focus after the FDA issued a Complete Response Letter for its bitopertin program, triggering a 22% one day share price drop and a shareholder rights investigation.
See our latest analysis for Disc Medicine.
Beyond the sharp reaction to the FDA Complete Response Letter and the shareholder rights investigation, Disc Medicine’s recent 7 day share price return of 8.47% and 30 day share price return of 8.02% sit alongside a 90 day share price return of 17.59% and a...